Precision Biosciences Inc is a biotechnology company focused on the development of innovative gene-editing technologies for therapeutic applications
The company employs its proprietary ARCUS platform, which utilizes a unique approach to genome editing, allowing for precise modifications in genetic material. By leveraging its expertise in gene therapies, Precision Biosciences aims to address a range of challenging diseases and conditions, including genetic disorders, cancer, and viral infections. The company is committed to advancing its pipeline of therapies through rigorous research and collaboration, ultimately striving to improve patient outcomes and contribute to the future of personalized medicine.
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
DTIL stock results show that Precision BioSciences missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
